Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study.
Dufour
Jean-François
JF
University Clinic for Visceral Surgery and Medicine, University of Berne, CH-3010 Berne, Switzerland. jf.dufour@insel.ch
Hoppe
Hanno
H
Heim
Markus H
MH
Helbling
Beat
B
Maurhofer
Olivier
O
Szucs-Farkas
Zsolt
Z
Kickuth
Ralph
R
Borner
Markus
M
Candinas
Daniel
D
Saar
Bettina
B
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D024221:Antineoplastic Protocols; D001557:Benzenesulfonates / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000628:therapy*; D002408:Catheters, Indwelling; D016461:Chemoembolization, Therapeutic; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000628:therapy*; D016685:Mitomycin / Q000627:therapeutic use; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D000077157:Sorafenib; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000097:blood
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D042461:Vascular Endothelial Growth Factor A; D009536:Niacinamide; D016685:Mitomycin; D004317:Doxorubicin; D000077157:Sorafenib